Bot Detector
IJPC Seal
Download FREE Sample Issue or Article
LEARN MORE
Subscribe Today
A subscription to IJPC provides on-line access to full-text, full-color, printable PDF copies of your subscribed issues, individual articles, and purchased archives.

Library Archives
Volume 24, 2020 Archive

Six issues from 2020 in one convenient archive.

  • Full-color, full-text PDF files of articles and formulations from the Journal.
  • Print or save articles for your research, marketing, and educational needs.
  • Log-in to your account for keyword or topical search and download.
  • Purchased items appear with download icon in contents and search results.

Only $30000


(Select Format)
Instant Online Access

This archive contains the following articles listed by volume, issue and page number:

Issues Included
Issue/Volume Title
January/February 2020
Vol. 24 No. 1
Volume 24, Number 1
March/April 2020
Vol. 24 No. 2
Volume 24, Number 2
May/June 2020
Vol. 24 No. 3
Volume 24, Number 3
July/August 2020
Vol. 24 No. 4
Volume 24, Number 4
September/October 2020
Vol. 24 No. 5
Volume 24, Number 5
November/December 2020
Vol. 24 No. 6
Volume 24, Number 6

Volume 24, 2020 Articles
Title/Author
(Click for Abstract / Details / Purchase)
Issue/​Page
View/Buy
PreScription: One Size Does Not Fit All!
Allen Loyd V Jr
Jan/Feb 2020
Pg. 4

Primary Engineering Controls in Pharmaceutical Compounding, Part 2: Biosafety Cabinets
Mulder Kyle
Jan/Feb 2020
Pg. 7-12

How to Qualify Container Closure Systems for Intended Use, Part 2: Choosing the Right Components for Container Closure Systems
Vaughn Stacey R
, Radwick Allison
Jan/Feb 2020
Pg. 14-19

Performing a United States Pharmacopeia Chapter <800> Compliant Assessment of Risk
Cabaleiro Joe
Jan/Feb 2020
Pg. 21-27

New and Improved!
Brunner Scott
Jan/Feb 2020
Pg. 28-29

Quality Control: Personal Protective Equipment for Use When Handling Hazardous Drugs
Dillon L R
Jan/Feb 2020
Pg. 30-36

Basics: Excipients Used in Nonsterile Compounding, Part 4: Antioxidants and Chelating Agents
Allen Loyd V Jr
Jan/Feb 2020
Pg. 38-43

Intravenous Admixture Preparation Considerations, Part 2: Incompatibilities and Factors Involved
Allen Loyd V Jr
Jan/Feb 2020
Pg. 44-50

Calculations
Stockton Shelly J
Jan/Feb 2020
Pg. 52

Amiodarone Hydrochloride 5 mg/mL in SyrSpend SF pH4 Cherry Flavored
Allen Loyd V Jr
Jan/Feb 2020
Pg. 54

Glutamine 250 mg/mL in SyrSpend SF pH4 Oral Suspension
Allen Loyd V Jr
Jan/Feb 2020
Pg. 55

Glycopyrrolate 0.2 mg/mL in Methylcellulose 1% and Syrup
Allen Loyd V Jr
Jan/Feb 2020
Pg. 56

Hydrocortisone 2%, Iodoquinol 1% Metronidazole 10%, and Zinc Oxide 2% in Polyethylene Glycol Ointment
Allen Loyd V Jr
Jan/Feb 2020
Pg. 57

Isoniazid 10 mg/mL in SyrSpend SF pH4
Allen Loyd V Jr
Jan/Feb 2020
Pg. 58

LCD 5%, Salicylic Acid 6% in Clobetasol Propionate 0.05% Ointment
Allen Loyd V Jr
Jan/Feb 2020
Pg. 59

Ondansetron Hydrochloride 0.8 mg/mL in SyrSpend SF pH4 Oral Suspension
Allen Loyd V Jr
Jan/Feb 2020
Pg. 60

Potassium Chloride 1 mmol/mL in Ora-Sweet SF
Allen Loyd V Jr
Jan/Feb 2020
Pg. 61

Progesterone 100-mg, Melatonin 1-mg, and L-Theanine 200-mg Slow-Release Capsules
Allen Loyd V Jr
Jan/Feb 2020
Pg. 62

Venlafaxine 15 mg/mL in Syrup
Allen Loyd V Jr
Jan/Feb 2020
Pg. 63

Long-term Physicochemical Stability of Concentrated Solutions of Isosorbide Dinitrate in Polypropylene Syringes for Administration in the Intensive Care Unit
Lardinois Benjamin
, Dimitriou Alexandre, Delcave Charlotte, Soumoy Laura, Jamart Jacques, Bihin Benoît, Hecq Jean-Daniel, Galanti Laurence M
Jan/Feb 2020
Pg. 64-68

Clinical Efficacy of a Topical Compounded Formulation in Male Androgenetic Alopecia: Minoxidil 10%, Finasteride 0.1%, Biotin 0.2%, and Caffeine Citrate 0.05% Hydroalcoholic Solution
Marotta James C
, Patel Gopesh, Carvalho Maria, Blakeney Samantha
Jan/Feb 2020
Pg. 69-76

Stability of Metronidazole Free-base Oral Suspensions Formulated with United States Pharmacopeia-grade Metronidazole Powder and Commercial Metronidazole Tablets
Jarouche Marian
, Ibrahim Martha, Pearson Jarryd, Low Mitchell, Rowe James
Jan/Feb 2020
Pg. 77-82

Compatibility of Melphalan in Iodinated Contrast Media
Shi Zhanquan
, Abruzzo Todd, Wanasathop Apipa, Li S Kevin
Jan/Feb 2020
Pg. 83-85

Errata - How to Qualify Container Closure Systems for Intended Use, Part 1 - IJPC 23(6) 454-461
Jan/Feb 2020
Pg. 86-87

View Sample
PreScription: Formal Appeals to United States Pharmacopeia Regarding USP Chapters <795>,<797>, and <825>: Part 1
Allen Loyd V Jr
Mar/Apr 2020
Pg. 92

Low-dose Naltrexone Therapy for Psoriasis
Weinstock Leonard B
, Cottel Jill, Aldridge Lindsey, Egeberg Alexander
Mar/Apr 2020
Pg. 94-96

Compounding Pearls -- Wound Care: Base Selection
Riepl Mike
Mar/Apr 2020
Pg. 98-102

Low-dose Pilocarpine Spray to Treat Xerostomia
Zur Eyal
Mar/Apr 2020
Pg. 104-108

A "North Star" for Pharmacy Compounders
Brunner Scott
Mar/Apr 2020
Pg. 110-113

Basics of Nonsterile Compounding: Excipients Used in Nonsterile Compounding, Part 5: Compounding Using Solvents and Cosolvent Systems
Allen Loyd V Jr
Mar/Apr 2020
Pg. 114-118

Intravenous Admixture Preparation Considerations, Part 3: Methods and Techniques to Decrease Incompatibilities
Allen Loyd V Jr
Mar/Apr 2020
Pg. 121-126

Calculations
Stockton Shelly J
Mar/Apr 2020
Pg. 128

Acetazolamide 25 mg/mL in SyrSpend SF pH4
Allen Loyd V Jr
Mar/Apr 2020
Pg. 130

Cholecalciferol 50,000 IU/mL in SyrSpend SF pH4
Allen Loyd V Jr
Mar/Apr 2020
Pg. 131

Glycopyrrolate 0.2 mg/mL in Ora-Plus:Ora-Sweet (1:1)
Allen Loyd V Jr
Mar/Apr 2020
Pg. 132

Minocycline Hydrochloride 10 mg/mL in SyrSpend SF pH4
Allen Loyd V Jr
Mar/Apr 2020
Pg. 133

Nitrofurantoin 2 mg/mL in SyrSpend SF pH4 Oral Suspension
Allen Loyd V Jr
Mar/Apr 2020
Pg. 134

Propylthiouracil 5 mg/mL in SyrSpend SF pH4
Allen Loyd V Jr
Mar/Apr 2020
Pg. 135

Quinidine Sulfate 10 mg/mL in SyrSpend SF pH4
Allen Loyd V Jr
Mar/Apr 2020
Pg. 136

Terbinafine 25 mg/mL in SyrSpend SF pH4
Allen Loyd V Jr
Mar/Apr 2020
Pg. 137

Topiramate 5 mg/mL in SyrSpend SF pH4
Allen Loyd V Jr
Mar/Apr 2020
Pg. 138

Valsartan 4 mg/mL in Syrup NF
Allen Loyd V Jr
Mar/Apr 2020
Pg. 139

The Effect of Manufacturer on the Compounding of Omeprazole Suspensions and Their Stability Assessment
Meissner Svenja
, Bansal Mahima, Dela Cruz Paula Donamae, Hanning Sara, Svirskis Darren
Mar/Apr 2020
Pg. 140-147

Comparison of Disintegrant-addition Methods on the Compounding of Orodispersible Tablets
Mahesparan Vishnu A/L
, Bin Abd Razak Fashli Syafiq, Ming Long Chiau, Uddin ABM Helal, Sarker Md Zaidul Islam, Bin Liew Kai
Mar/Apr 2020
Pg. 148-155

Physicochemical Stability of Ternary Mixtures of Sufentanil, Baclofen, and Ropivacaine in Polypropylene Syringes for Intrathecal Analgesia
Sorrieul Jérémy
, Robert Julien, Chapel Fanny, Gossye Thomas, Devys Catherine
Mar/Apr 2020
Pg. 156-162

Feasibility Study of Asthma Cream
Kuang Andrew
Mar/Apr 2020
Pg. 163-167

Percutaneous Absorption of Lorazepam, Diphenhydramine Hydrochloride, and Haloperidol from ABH Gel
Dahal Amit
, Neupane Rabin, Boddu Sai HS, Renukuntla Jwala, Khupse Rahul, Dudley Richard
Mar/Apr 2020
Pg. 168-175

PreScription: Formal Appeals to United States Pharmacopeia Regarding USP Chapters <795>, <797>, and <825>: Part 2
Allen Loyd V Jr
May/Jun 2020
Pg. 180

Compounding Pearls -- Wound Care: Diabetic Foot Ulcers, Part 1
Riepl Mike
May/Jun 2020
Pg. 182-186

Compounding Pearls -- Wound Care: Burn Healing, Part 1
Riepl Mike
May/Jun 2020
Pg. 188-193

Compounded Beta-blocker Nasal Spray for Treatment of Acute Migraine: A New Therapeutic Modality
Hagan John C III
, Everett Eric, Chamberlain Tyler
May/Jun 2020
Pg. 194-197

U.S. Food and Drug Administration Takes Aim (Again) at Animal Compounding: Draft Guidance for Industry #256 Lacks Authority, Will Increase Costs, and Put Pets at Risk
Brunner Scott
May/Jun 2020
Pg. 198-199

Quality Control: Photostability of Compounded Preparations
Allen Loyd V Jr
May/Jun 2020
Pg. 200-205

Basics: Excipients Used in Nonsterile Compounding, Part 6: Compounding with Viscosity-increasing Agents
Allen Loyd V Jr
May/Jun 2020
Pg. 206-212

Sterile Basics: Intravenous Admixture Preparation Considerations, Part 4: Particulates
Allen Loyd V Jr
May/Jun 2020
Pg. 215-220

Calculations
Stockton Shelly J
May/Jun 2020
Pg. 222

Baclofen 10 mg/mL in SyrSpend SF pH4
Allen Loyd V Jr
May/Jun 2020
Pg. 224

Dexamethasone 1 mg/mL in SyrSpend SF pH4
Allen Loyd V Jr
May/Jun 2020
Pg. 225

Diphenylcyclopropenone 0.1% or 3% in Isopropranol
Allen Loyd V Jr
May/Jun 2020
Pg. 226

Ibuprofen 400-mg and Cyclobenzaprine 2.5-mg Capsules
Allen Loyd V Jr
May/Jun 2020
Pg. 227

Monsel's Solution, Gel, and Paste
Allen Loyd V Jr
May/Jun 2020
Pg. 228

Prednisolone 1 mg/mL in SyrSpend SF pH4
Allen Loyd V Jr
May/Jun 2020
Pg. 229

Sildenafil 2.5 mg/mL in Methylcellulose 1%:Syrup (1:1) Oral Suspension
Allen Loyd V Jr
May/Jun 2020
Pg. 230

Tetracycline Hydrochloride 25 mg/mL in SyrSpend SF pH4
Allen Loyd V Jr
May/Jun 2020
Pg. 231

Ursodiol 100 mg/mL in Cod Liver Oil, Veterinary
Allen Loyd V Jr
May/Jun 2020
Pg. 232

Venlafaxine 15 mg/mL in Ora-Plus:Ora-Sweet (1:1) Suspension
Allen Loyd V Jr
May/Jun 2020
Pg. 233

Comparative Stability Study of Unit-dose Vancomycin Hydrochloride Oral Solutions in Plastic Capped Oral Syringes and Plastic Sealed Dosage Cups
Brown Stacy
, Lewis Paul
May/Jun 2020
Pg. 234-237

Physical Compatibility of Medications Used in Critically Ill Patients with Balanced Fluid Solutions
Wilder Alyson G
, Foushee Jaime A, Fox Laura M, Navalle Jordan, Wright Adrienne M, Greer Megan A
May/Jun 2020
Pg. 238-241

Physicochemical Stability and Compatibility of Revefenacin (LAMA) and Formoterol Fumarate (LABA) Inhalation Solution Admixture
Ngim Kenley
, Patel Jalpa
May/Jun 2020
Pg. 242-245

Alcohol-free Extemporaneous Formulations of Furosemide Are Chemically and Physically Stable in Ora-Blend Products for 30 Days
Svirskis Darren
, Jaffer Johaina, Agarwal Priyanka, Khan Ayeshah, Kaur Jaskarn, Cheng Alan, Hanning Sara
May/Jun 2020
Pg. 246-251

Stability of Azathioprine, Clonidine Hydrochloride, Clopidogrel Bisulfate, Ethambutol Hydrochloride, Griseofulvin, Hydralazine Hydrochloride, Nitrofurantoin, and Thioguanine Oral Suspensions Compounded with SyrSpend SF pH4
Polonini Hudson
, Loures da Silva Sharlene, Neves Cunha Carolina, de Oliveira Ferreira Anderson, Anagnostou Korina, Dijkers Eli
May/Jun 2020
Pg. 252-262

PreScription: COVID-19 and Compounding Pharmacists
Allen Loyd V Jr
Jul/Aug 2020
Pg. 268

Safety Standards in Pharmaceutical Compounding, Part 1: The Occupational Safety and Health Administration
Greeson Nicole MH
, Mixon William, Allan W Chris
Jul/Aug 2020
Pg. 270-276

Compounding Pearls -- Wound Care: Diabetic Foot Ulcers, Part 2
Riepl Mike
Jul/Aug 2020
Pg. 278-281

Compounding Pearls -- Wound Care: Burn Healing, Part 2
Riepl Mike
Jul/Aug 2020
Pg. 282-285

Pharmacies on the Frontline: Responding to the COVID-19 Pandemic
McElhiney Linda F
Jul/Aug 2020
Pg. 287-295

Finally: A Final U.S. Food and Drug Administration Memorandum of Understanding, but It's Flawed
Brunner Scott
Jul/Aug 2020
Pg. 296-297

Quality Control: Rapid Sterility Testing for Compounding Pharmacies
Taylor Andrew
Jul/Aug 2020
Pg. 299-303

Sterile Basics: Intravenous Admixture Preparation Considerations, Part 5: pH Considerations
Allen Loyd V Jr
Jul/Aug 2020
Pg. 305-309

Calculations
Stockton Shelly J
Jul/Aug 2020
Pg. 310

Benzonatate 50 mg/mL in Ora-Sweet
Allen Loyd V Jr
Jul/Aug 2020
Pg. 312

Cyclobenzaprine 5-mg/g and Guaifenesin 10-mg/g Transdermal Cream
Allen Loyd V Jr
Jul/Aug 2020
Pg. 313

Doxepin Hydrochloride 5% in Cetaphil Cream
Allen Loyd V Jr
Jul/Aug 2020
Pg. 314

Hydrocortisone Hemisuccinate 2 mg/mL or Hydrocortisone Sodium Phosphate 2 mg/mL in SyrSpend SF pH4
Allen Loyd V Jr
Jul/Aug 2020
Pg. 315

Hydroxychloroquine Sulfate 25 mg/mL in Ora-Plus:Ora-Sweet SF
Allen Loyd V Jr
Jul/Aug 2020
Pg. 316

Hydroxyzine (Pamoate) 25-mg/mL Oral Suspension
Allen Loyd V Jr
Jul/Aug 2020
Pg. 317

Lisinopril 1 mg/mL in SyrSpend SF pH4
Allen Loyd V Jr
Jul/Aug 2020
Pg. 318

Lorazepam 1 mg/mL in a Nonaqueous Cosolvent Vehicle
Allen Loyd V Jr
Jul/Aug 2020
Pg. 319

Sumatriptan, Lidocaine Hydrochloride, Dexamethasone, Pentoxifylline, and Ibuprofen Transdermal Cream (Migraine Cream)
Allen Loyd V Jr
Jul/Aug 2020
Pg. 320

Tramadol Hydrochloride 10 mg/mL in SyrSpend SF pH4
Allen Loyd V Jr
Jul/Aug 2020
Pg. 321

Incorporating Quality Assurance in Pharmaceutical Compounding-related Courses in the PharmD Curricula
Hossain Mohammad Faisal
, Levesque Dan, Frye John, Rashid Mamoon
Jul/Aug 2020
Pg. 322-326

Stability of Extemporaneous Oral Tramadol, Fluoxetine, and Doxycycline Suspensions in SyrSpend SF pH4
Espana B
, Joseph-Tornabène F, Jaquet Cécile, Perrot S, Prouillac C
Jul/Aug 2020
Pg. 327-336

Evaluation of the Efficacy and Stability of Compounded Pentoxifylline-containing XemaTop for Psoriasis
Song Guiyun
, Ip Kendice, Shan Ashley, Banov Daniel, Bassani August S
Jul/Aug 2020
Pg. 337-345

Single Center Experience with Robot Technologies for Sterile Compounding: A Retrospective Review
Milibari Loay
, Cotugno Michael, Belisle Caryn, Rocchio Megan, Patterson Robert F, Chacon Pablo, Fanikos John, Vo Peter
Jul/Aug 2020
Pg. 346-351

Safety and Efficacy Studies, Pharmacy Education, and the NASEM Report on Compounded Topical Pain Creams
Allen Loyd V Jr
Sep/Oct 2020
Pg. 356

Cocamidopropyl Betaine Surfactant 0.075% Solution in Physiological Serum for Hygiene Process of COVID-19 Intubated Patients
Nogales Luis Marcos
, Jiménez Labaig Luis, Abarca Lachén Edgar, Gil Melcón María, López-Nieves Marisol
Sep/Oct 2020
Pg. 358-364

Topical Cholesterol/Simvastatin Gel for the Treatment of CHILD Syndrome in an Adolescent
Cho Sung Kyung
, Ashworth Lisa Diggs, Goldman Shauna
Sep/Oct 2020
Pg. 367-369

Safety Standards in Pharmaceutical Compounding, Part 2: A Closer Look at Agency Information, Oversight, and Assistance
Greeson Nicole MH
, Mixon William, Allan W Chris
Sep/Oct 2020
Pg. 371-379

Houston, We Have a Study': History-making African Research Relies on a Maverick Texas Pharmaceutical Compounder
Lovell Nancy
Sep/Oct 2020
Pg. 380-385

An Unconscionable, Unnecessary Fight
Bruner Scott
Sep/Oct 2020
Pg. 386-387

Basics of Compounding: Excipients Used in Nonsterile Compounding, Part 7: Compounding with Surfactants
Allen Loyd V Jr
Sep/Oct 2020
Pg. 388-395

Intravenous Admixture Preparation Considerations, Part 6: pH Considerations -- Applications
Allen Loyd V Jr
Sep/Oct 2020
Pg. 397-402

Calculations
Stockton Shelly J
, Bui Phi H
Sep/Oct 2020
Pg. 404

Ketamine 60.6-mg/mL, Acepromazine 0.6-mg/mL, and Xylazine 6.67-mg/mL Injection (Vet-Rat and Hamster); Ketamine 6.06-mg/mL, Acepromazine 0.06-mg/mL, and Xylazine 0.667-mg/mL Injection (Vet-Mouse)
Allen Loyd V Jr
Sep/Oct 2020
Pg. 406

Levofloxacin 50 mg/mL in SyrSpend SF pH4 Oral Suspension
Allen Loyd V Jr
Sep/Oct 2020
Pg. 407

Always the Right Dose? Content Uniformity in Over 100 Different Formulations Tested
Dijkers Eli
, Polonini Hudson, de Oliveira Ferreira Anderson
Sep/Oct 2020
Pg. 408-412

Physicochemical Stability of Compounded Allopurinol Suspensions in PCCA Base, SuspendIt
Pramar Yashoda V
, Mandal Tarun K, Bostanian Levon A, Le Giang, Morris Tommy C, Graves Richard A
Sep/Oct 2020
Pg. 413-419

Biotin Regulates Colonization and Growth of Candida albicans in the Catheter Lumen During Nutrient Infusions
Ohara Hiroshi
, Matsuzaki Tetsuya, Ochiai Tatsuya, Hayasaka Masataka
Sep/Oct 2020
Pg. 420-425

Efficacy of an Automated Robotic Cleaning Device for Compounding Pharmacies
Polonini Hudson
, Dijkers Eli CF, Ferreira Anderson O, da Silva Sharlene L, Araújo Paulo Victor C, Koulouridas Savvas
Sep/Oct 2020
Pg. 426-433

Evaluation of the Efficacy and Superiority of Different Vial Rubber Closure Disinfection Techniques
Bjornstad Matthew
, Kosinski Tracy, Burlage Robert
Sep/Oct 2020
Pg. 434-438

PreScription: The NASEM cBHT Report, Part 1
Allen Loyd V Jr
Nov/Dec 2020
Pg. 444

NASEM Report on Compounded Topical Pain Creams
Allen Loyd V Jr
Nov/Dec 2020
Pg. 446-448

Safety Standards in Pharmaceutical Compounding, Part 3: Fire Safety
Allen W Chris
, Greeson Nicole MH, Mixon William
Nov/Dec 2020
Pg. 451-458

Establishing a Structured Pharmacy Training Program in Sterile Compounding
Dirbas Muhannad
, AbuSara Aseel K, Whiyabi Shatha, Harb Rema, Telfah Shorouq
Nov/Dec 2020
Pg. 460-465

Gender Bias in the Treatment of Menopausal Women: I am Hot as Hell and Not Going to Take It Anymore, Part 1
DeRosa Angela
Nov/Dec 2020
Pg. 466-470

Intravenous Admixture Preparation Considerations, Part 7: Stability Issues
Allen Loyd V Jr
Nov/Dec 2020
Pg. 473-478

Calculations
Drinnon Stephen D
, Stockton Shelly J
Nov/Dec 2020
Pg. 480

Stability of Compounded Diltiazem Hydrochloride in Cream, Ointment, and Gel Formulations for Topical Use
Teimouri Arezou
, Yeung Pollen, Agu Remigius U
Nov/Dec 2020
Pg. 482-490

Analysis of Extemporaneously Compounded Nasal Preparations Prescribed by Latvian Otorhinolaryngologists and General Practitioners and Comparison with German Formulations
Kiselova Olga
, Maurina Baiba, Sidlovska Venta
Nov/Dec 2020
Pg. 491-500

Drug-release Assessment of Compounded Topical Nifedipine and Diltiazem in Commonly Used Bases for Wound Healing
Teimouri Arezou
, Yeung Pollen, Agu Remigius U
Nov/Dec 2020
Pg. 501-508

Investigation of Filler Effects on the Compounding of Freeze-dried Orodispersible Tablets Containing Annona muricata Extract
Azman Syahiera Ezzah Noor
, Abd Razak Fashli Syafiq, Kamal Wan Hamirul Bahrin Wan, Zheng Gan Kok, Ming Long Chiau, Uddin ABM Helal, Sarker Zaidul Islam, Bin Liew Kai
Nov/Dec 2020
Pg. 509-514

Development and Evaluation of an Anti-aging Cosmetic Formulation Exploring Antioxidant Potential of Vitis vinifera L.
Carneiro Jaqueline
, Marques Gonçalves Melissa, Vicente Pereira Airton
Nov/Dec 2020
Pg. 515-518

Development of Stable and Simple Finasteride 333-μg/mL Suspensions that Minimize Occupational Exposure
Ma Nathan
, Perks William, Law Shirley, Iazzetta John, Walker Scott
Nov/Dec 2020
Pg. 519-527

Erratum: IJPC. 2020; 24(4): 327 Stability of Extemporaneous Oral Tramadol, Fluoxetine, and Doxycycline Suspensions in SyrSpend SF PH4
Nov/Dec 2020
Pg. 527

View Sample
Return to Top